Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Agomelatine Prodrug
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Seaport Therapeutics Doses First Participant in Phase 1 of GlyphAgo (SPT-320)
Details : Agomelatine's mechanism of action involves its actions as a melatonin receptor agonist and a 5-HT2C receptor antagonist, which increase dopamine and norepinephrine in pateints with GAD.
Product Name : SPT-320
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 11, 2025
Lead Product(s) : Agomelatine Prodrug
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SPT-300
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Premier Research Group
Deal Size : Inapplicable
Deal Type : Inapplicable
SPT-300 (GlyphAllo) Safety & Efficacy In Major Depressive Disorder ± Anxious Distress
Details : SPT-300 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Depressive Disorder, Major.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 15, 2025
Lead Product(s) : SPT-300
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Premier Research Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Allopregnanolone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I/ Phase II
Sponsor : General Atlantic
Deal Size : $225.0 million
Deal Type : Series B Financing
Seaport Therapeutics Closes $225M Series B Financing Round
Details : Seaport will use the proceeds to advance its clinical-stage pipeline of first and best-in-class medicines, including SPT-300 (glyph allopregnanolone), an oral prodrug of allopregnanolone.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 21, 2024
Lead Product(s) : Allopregnanolone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I/ Phase II
Sponsor : General Atlantic
Deal Size : $225.0 million
Deal Type : Series B Financing
Lead Product(s) : Glyph Allopregnanolone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
PureTech Founded Entity Seaport Therapeutics Presents Data from Multiple SPT-300 Trials
Details : SPT-300 (glyph-allopregnanolone), an oral prodrug of allopregnanolone, an endogenous neurosteroid, a GABAA PAM, is in clinical stage development for the treatment of mood and anxiety disorders
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 09, 2024
Lead Product(s) : Glyph Allopregnanolone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable